Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Good Start Genetics, PerkinElmer Collaboration Expands Access to Genetic Carrier Screening Tests

Published: Monday, March 17, 2014
Last Updated: Monday, March 17, 2014
Bookmark and Share
Strategic agreement will broaden access to GoodStart Select™ tests to include obstetrics and gynecology and maternal fetal medicine physicians.

GoodStart Select is a menu of genetic carrier screening tests offered by Good Start Genetics that uses sophisticated technologies, including proprietary next-generation DNA sequencing (NGS), to provide highly accurate and clinically actionable genetic information to reproductive partners planning a pregnancy. Test results by GoodStart Select have been shown to provide higher mutation detection rates and fewer missed carriers than traditional screening technologies.

"Our continued success with GoodStart Select in the IVF setting demonstrates the clinical value of our robust menu of tests for guideline-recommended genetic disorders. We are excited that PerkinElmer has chosen GoodStart Select as their genetic carrier screening offering of choice," said Don Hardison, president and chief executive officer of Good Start Genetics. “Collaborating with PerkinElmer will allow us to reach more of the 60 million reproductive age women who are candidates for genetic carrier screening, and ultimately help more couples better assess their risks of, and options to avoid, having a baby with a debilitating or fatal inherited genetic disorder ."

Under the terms of the collaboration agreement, PerkinElmer will serve as the exclusive commercial partner of Good Start Genetics in the sales and marketing of GoodStart Select to targeted OBGYN and MFM physicians in the United States. The collaboration expands access to the GoodStart Select tests to ordering physicians that are not within Good Start Genetics’ current commercial market of in vitro fertilization and broadens PerkinElmer’s extensive prenatal screening menu to include the highly-validated genetic carrier screening tests included in the GoodStart Select menu.

"PerkinElmer is committed to offering innovative prenatal screening technology as part of our comprehensive diagnostics portfolio,” said Jim Corbett, president, Human Health, PerkinElmer. “GoodStart Select further expands our maternal fetal health offerings and enables us to provide even more meaningful tools and clinically actionable information and insights to physicians and patients. We look forward to working with Good Start Genetics to extend genetic carrier screening options for those persons planning a pregnancy.

Professional societies, including the American Congress of Obstetricians & Gynecologists (ACOG), the American College of Medical Genetics and Genomics (ACMG) and national Jewish advocacy societies have published recommendations for carrier screening to detect potential genetic disorders that are relatively common in certain ethnicities. GoodStart Select is designed to identify known, pathogenic mutations for all inherited genetic disorders recommended for testing by the leading reproductive medicine societies and influential advocacy groups, irrespective of a patient’s ethnicity. By arming physicians and patients with this personalized genetic information, GoodStart Select can help reproductive partners to better assess their risk of, and options to avoid, having a child with a debilitating or fatal inherited genetic disorder.



Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PerkinElmer, Sofie Biosciences Announce Benchtop PET Imaging Partnership
Preclinical PET imaging instruments in benchtop format help support high performance disease research, drug discovery and clinical translational applications.
Tuesday, June 10, 2014
PerkinElmer to Host Revolutionaries for Global Health Summit
Company to assemble thought leaders to share pioneering personalized health research and innovations.
Wednesday, May 01, 2013
PerkinElmer Expands Reagent Portfolio for Faster Identification of Epigenetic Drug Candidates
The company announced the launch of four new cellular assay kits to help identify and characterize possible drug candidates targeting epigenetic enzymes related to key disease states.
Tuesday, February 07, 2012
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
Crystal Clear Images Uncover Secrets of Hormone Receptors
NIH researchers gain better understanding of how neuropeptide hormones trigger chemical reactions in cells.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!